Full Text View
Tabular View
Study Results
Related Studies
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
This study has been completed.
Study NCT00361504   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: August 4, 2006   Last Updated: September 14, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoarthritis, Hip
Osteoarthritis, Knee
Lower Back Pain
Pain
Additional conditions recognized in this trial
Back Pain
Low Back Pain
Osteoarthritis
More general conditions related to this trial
Arthritis
Joint Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Rheumatic Diseases
Signs and Symptoms
Interventions listed in this trial
tapentadol (CG5503) PR
oxycodone CR
Additional drug interventions recognized in this trial
Oxycodone
More general drug interventions related to this trial
Analgesics
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Grünenthal GmbH


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services